DALY II Japan/MB-CART2019.1 for DLBCL
A phase 2 trial of Zamtocabtagene autoleucel in diffuse large b-cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.
Overview
DALY II Japan/MB-CART2019.1 for DLBCL is a phase 2 interventional study registered as NCT07288879 by Miltenyi Biomedicine GmbH, with 31 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-01-31. Interventions recorded: MB-CART2019.1. Conditions listed: DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy. No results are recorded here; the registry entry is the source.
Setting
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.
Phase
Phase 2
Sponsor
Miltenyi Biomedicine GmbH
Registry
Enrolled
31
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
- TrialDALY II USA/ MB-CART2019.1 for DLBCL
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Diffuse large B-cell lymphoma.
- TrialEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Diffuse large B-cell lymphoma.
- CancerPrimary CNS lymphoma